The predictive value of serum concentrations of anti-Müllerian hormone for oocyte quality, fertilization, and implantation

Edson Borges¹,², Daniela P. A. F. Braga¹,²,³, Amanda Setti¹,², Rita de Cássia Figueira¹, Assumpção Iaconelli Jr.¹,²

¹ Fertility Medical Group, São Paulo, SP - Brazil
² Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida, São Paulo, SP - Brazil
³ Disciplina de Urologia, Área de Reprodução Humana, Departamento de Cirurgia, Universidade Federal de São Paulo, São Paulo, SP - Brazil

ABSTRACT

Objective: This study aimed to identify a possible correlation between serum levels of anti-Müllerian hormone (AMH) and oocyte quality, embryo developmental competence, and implantation potential.

Methods: 4488 oocytes obtained from 408 patients undergoing ICSI cycles were evaluated. Oocyte dimorphisms, embryo quality on days two and three, blastocyst formation competence, fertilization rates, implantation rates, and pregnancy rates were correlated with serum levels of AMH using Pearson's correlation coefficient and regression analysis.

Results: A positive correlation was observed between serum levels of AMH and number of retrieved oocytes (CC: 0.600, \( p<0.001 \)), fertilization rate (CC: 0.595, \( p=0.048 \)), and number of obtained embryos (CC: 0.495, \( p<0.001 \)). AMH did not affect the quality of cleavage stage embryos or the chance of blastocyst formation. However, AMH levels affected oocyte quality (OR: 0.75, CI: 0.44-0.96, \( p<0.001 \)), and implantation (CC: 0.116, \( p=0.031 \)) and pregnancy (OR: 1.22, CI: 1.03-1.53, \( p<0.001 \)) rates.

Conclusion: Serum levels of AMH are a useful predictor of ovarian response to COS, oocyte quality, and fertilization. However, AMH levels may also compromise clinical outcomes; lower AMH levels did not impair embryo development.

Keywords: Oocyte, blastocyst, embryo implantation, pregnancy, COS cells, anti-Müllerian hormone

INTRODUCTION

Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance, is a peptide growth factor and a member of the tissue growth factor beta superfamily. In male fetuses, the development of the internal reproductive tract requires the presence of AMH to cause the involution of the Müllerian ducts, the anlagen of the female reproductive tract (Nussey & Whitehead, 2001). In females, fetal AMH is produced after 36 weeks of gestation by the granulosa cells of primary, secondary, pre-antral, and early antral follicles (Durlinger et al., 1999; Rajpert-De Meyts et al., 1999; Weenen et al., 2004), and it continues to be expressed until the follicles reach the antral phase and are more than 2mm in diameter (Messinis, 2006).

It has been suggested that AMH inhibits the initiation of primordial follicle growth from the ovarian reserve (Weenen et al., 2004; Nilsson et al., 2007). In mice, it decreases the sensitivity of follicles to FSH, thereby inhibiting FSH-induced antral follicle growth (Durlinger et al., 2002). Although not fully understood, AMH may play a role in regulating the recruitment of cohorts of antral follicles (reviewed in Baerwald et al., 2012).

The anti-Müllerian hormone, barely detectable at birth in females, peaks after puberty (Rajpert-De Meyts et al., 1999). In line with this, AMH levels have shown greater sensitivity to ovarian aging (de Vet et al., 2002) and a stronger relationship with the number of early antral follicles (Fanchin et al., 2003). In fact, the serum level of AMH has been established as the most valuable marker of ovarian reserve, as it correlates highly with the baseline antral follicle count. In addition, AMH levels are a useful predictor of ovarian response to controlled ovarian stimulation (COS) (van Rooij et al., 2002; Eldar-Geva et al., 2005; Tremellen et al., 2005; Nakhuda et al., 2006; Nakhuda et al., 2007; Nardo et al., 2009). Previous studies found that, besides ovarian response to COS, the serum level of AMH can be used as a predictor of severity of endometriosis (Shebl et al., 2009). Anti-Müllerian hormone measurements also offer relatively high specificity and sensitivity as a diagnostic marker for polycystic ovary syndrome (Pigny et al., 2006). Moreover, as AMH declines with age and continues to decline until it reaches a stage in which it becomes undetectable in serum after menopause, it has also been suggested that a single AMH measurement may be a good predictor of the onset of menopause in aging women.

Despite being a good marker of ovarian response, AMH fails to predict the outcome of pregnancy (Lie Fong et al., 2008; Talebian et al., 2008; Riggs et al., 2011), since, as suggested by Loh & Maheshwari (2011), it cannot predict the quality of the oocyte. However, previously published reports have focused on the assessment of embryo quality (Hazout et al., 2005; Silberstein et al., 2006; Smeenk et al., 2007; Lie Fong et al., 2008; Talebian et al., 2008) rather than oocyte quality, considering specifically intracytoplasmic and extracytoplasmic oocyte defects.

In fact, the number of retrieved oocytes and the quality of oocytes and embryos significantly impact the outcomes of assisted reproductive technology (ART). It has been reported that, although the percentage of embryo transfers that leads to deliveries has steadily increased, in the last years, the vast majority of embryos that are produced in vitro fail to develop into an infant (Kovalevsky & Patrizio, 2005). Therefore, the goal of the present study was to identify a possible correlation between serum levels of AMH and the following: (i) oocyte quality, (ii) embryo developmental competence, and (iii) implantation potential.

MATERIALS AND METHOD

Study Design

This study analyzed the correlation between serum levels of AMH and (i) maternal age, (ii) maternal BMI, (iii) FSH dose for ovarian stimulation, (iv) number of aspirated follicles, (v) number of retrieved oocytes, (vi) number of retrieved MII mature oocytes, (vii) oocyte quality, (viii) fertilization rate, (ix) number of obtained embryos, (x)
number of obtained high-quality embryos, (xi) embryo quality on day two, (xii) embryo quality on day three, (xiii) chance of blastocyst formation, (xiv) number of transferred embryos, (xv) implantation rate, and (xvi) pregnancy rate.

Intra- and extracytoplasmic defects were recorded before sperm injection for purposes of oocyte quality assessment. In embryo quality evaluation, the embryos were categorized as high or low quality on days two, three, and five. Fertilization rate was defined based on the number of oocytes presenting two clearly distinct pronuclei 18 hours after ICSI divided by the number of injected oocytes. Implantation rate was calculated as the number of gestational sacs divided by the number of embryos transferred per patient. Clinical pregnancy was defined by the presence of a gestational sac with heartbeat viewed on ultrasound examination 4-6 weeks after embryo transfer.

The assessment included 4488 oocytes obtained from 408 patients undergoing ICSI cycles between January 2011 and August 2013. Serum AMH tests were included as a standard measure in the IVF program. Tests were run prior to the start of each cycle and AMH levels were recorded. The oocytes were evaluated immediately before sperm injection, and the embryos were evaluated 16-18h post-ICSI and on days two, three and five of development.

Inclusion criteria were as follows: women of good physical and mental health, with regular menstrual cycles of 25-35 days, normal basal FSH and LH levels and BMI lower than 30kg/m^2, presence of both ovaries and an intact uterus, undergoing the first or second ICSI cycle. Patients with endometriosis or gynecological/medical disorders and a negative result in a screening for sexually transmitted diseases were excluded. All cases of severe alteration in spermatogenesis, including frozen and surgically retrieved sperm, were also excluded from the study.

The implantation rate was defined as the total number of gestational sacs divided by the total number of transferred embryos. Clinical pregnancy was defined as the presence of a gestational sac viewed on ultrasound examination 4-6 weeks after embryo transfer.

The patients gave written consent before joining the study and agreed to share the outcomes of their cycles for research purposes. The local review board approved the study.

Controlled ovarian stimulation
Controlled ovarian stimulation was achieved using a daily dose of recombinant FSH (Gonal-F; Serono, Geneva, Switzerland) starting on day three of the cycle. Pituitary down-regulation was performed using a GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland), started when at least one follicle ≥14mm was viewed.

Follicular growth was monitored using transvaginal ultrasound examination starting on day four of gonadotropin administration. When adequate follicular growth and serum E2 levels were observed, recombinant hCG (Ovidrel; Serono, Geneva, Switzerland) was administered to trigger final follicular maturation. The oocytes were collected 35 hours after hCG administration through transvaginal ultrasound-guided ovum pick-up.

Preparation of oocytes
The retrieved oocytes were maintained in culture medium (Global® for fertilisation, LifeGlobal, Connecticut, USA) supplemented with 10% protein supplement (LGPS, LifeGlobal, Connecticut, USA) and covered with paraffin oil (Paraffin oil P.G., LifeGlobal, Connecticut, USA) for two to three hours before the removal of cumulus cells. The surrounding cumulus cells were removed after exposure to a HEPES-buffered medium containing hyaluronidase (80IU/mL, LifeGlobal, Connecticut, USA). The remaining cumulus cells were gently removed with a hand-drawn Pasteur pipette (Humagen Fertility Diagnostics, Charlottesville, USA).

Oocyte morphology was assessed immediately before sperm injection (4 hours after retrieval) using an inverted Nikon Diaphot microscope (Eclipse TE 300; Nikon®, Tokyo, Japan) with a Hoffmann modulation contrast system under 400X magnification. The following oocyte dysmorphisms were recorded: intra-cytoplasmic defects such as (i) cytoplasm color, (ii) vacuoles in the ooplasm, (iii) aggregates of smooth endoplasmic reticulum clusters (ERC) in the ooplasm and (iv) retractile bodies; and extracytoplasmic defects such as (i) large perivitelline space (PVS), (ii) PVS granularity, (iii) zona pelludica (ZP) abnormalities, (iv) shape abnormalities, and (v) fragmented polar body (PB).

Oocytes releasing the first polar body were considered mature and were used for ICSI.

Intracytoplasmic sperm injection
Intracytoplasmic sperm injection was performed in a microinjection dish prepared with 4-µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on the heated stage of an inverted microscope (37.0±0.5°C). Approximately 16 hours after ICSI, fertilization was confirmed by the presence of two pronuclei and the extrusion of the second polar body. Embryos were maintained in a 50-µL drop of culture medium (Global®, LifeGlobal, Connecticut, USA) supplemented with 10% protein supplement and covered with paraffin oil in a humidified atmosphere under 6% CO₂ at 37°C for three days.

Embryo morphology evaluation
Embryo morphology was assessed 16-18h post-ICSI and on the mornings of days two, three and five of embryo development using an inverted Nikon Diaphot microscope (Eclipse TE 300; Nikon, Tokyo, Japan) with a Hoffmann modulation contrast system under 400X magnification.

Cleavage stage morphology was assessed based on the following parameters: number of blastomeres, percent fragmentation, variation in blastomere symmetry, presence of multinucleation, and defects in the zona pelludica and cytoplasm. High-quality cleavage stage embryos had to show the following characteristics: 4 cells on day two or 8-10 cells on day three, <15% fragmentation, symmetric blastomeres, absence of multinucleation, colorless cytoplasm with moderate granulation and no inclusions, absence of perivitelline space granularity and absence of zona pelludica dysmorphism. Embryos lacking any of these characteristics were considered to be of low quality.

In blastocyst formation assessment the embryos were given a numerical score from 1 to 6 based on their degree of expansion and hatching statuses as follows: 1, an early blastocyst with a blastocoel that was less than half the volume of the embryo; 2, a blastocyst with a blastocoel that was greater than half the volume of the embryo; 3, a full blastocyst with a blastocoel that completely filled the embryo; 4, an expanded blastocyst; 5, a hatching blastocyst; and 6, a hatched blastocyst. Embryos receiving scores of 3 and greater were considered a full blastocyst.

Blood collection and Anti-Müllerian hormone analysis
When the patients visited the outpatient department, serum AMH levels were obtained, regardless of the menstrual phase, using a human AMH ELISA Kit (CUSABIO, Wuhan, China).

Blood samples were collected by peripheral venipuncture and centrifuged at 1000×g, 4°C, for 15 minutes, within 30
minutes of collection; the plasma portion was removed and assayed.

The human AMH ELISA Kits were used according to supplier instructions. The intra- and inter-assay coefficients of variation for all assays were <10 and 15%, respectively. Limits of detection were: 1ng/mL-75ng/mL.

Statistical analysis
Cycle and patient characteristics were expressed as the mean ± standard deviation for continuous variables; percentages were used for categorical variables.

Pearson’s correlation coefficient was used to evaluate the relationship between serum AMH levels and continuous variables. The results were expressed in the form of correlation coefficients (CC) and p-values.

Binary regression analysis was performed to evaluate the influence of AMH levels on pregnancy rates, embryo quality, blastocyst formation, and oocyte defects. These regressions were adjusted for female age, total level of FSH used in controlled ovarian stimulation, and the initial dose of FSH, as these are potentially confounding factors in the association between AMH level and the evaluated variables. The results were expressed as odds ratios (OR), 95% confidence intervals (CI) and p-values.

Significance was assigned to events with a p-value <0.05. Data analysis was carried out on Minitab Statistical Software (version 14).

RESULTS
Patient and cycle characteristics were as follows: maternal age: 37.7±5.4 (20-43) years, paternal age: 39.0±6.7 (24-65) years; body mass index (BMI): 24.4±3.9 (14.2-37.2); total dose of FSH administered in ovarian stimulation: 2370.9±855.3 (1900-3450) IU; number of aspirated oocytes: 6.7±7.4 (1-25); number of retrieved mature oocytes: 5.9±6.2 (1-18); fertilization rate: 82.7±20.8% (10-100); embryos obtained: 4.5±5.5 (1-16); high-quality embryos obtained: 1.5±1.1 (1-5); embryos transferred: 1.0±1.8 (1-3); implantation rate (%): 22.0±40.2 (0-100); and pregnancy rate: 28.9%.

The causes of infertility were as follows: male factor (146/408:35.8%), tubal factor (26/408:6.4%), unexplained infertility (29/408:7.1%), polycystic ovary syndrome (PCOS, 25/408:6.1%), female factor (127/408:31.1%), and others (55/408:13.5%).

As expected, an inverse correlation was found between serum AMH levels and number of aspirated follicles (CC: 0.626, p<0.001), number of retrieved oocytes (CC: 0.600, p<0.001), number of mature oocytes (CC: 0.588, p<0.001), fertilization rate (CC: 0.595, p=0.048), number of obtained embryos (CC: 0.495, p<0.001), number of high-quality embryos (CC: 0.504, p<0.001), number of transferred embryos (CC: 0.221, p<0.001), and implantation rate (CC: 0.116, p=0.031) (Table 1).

Serum levels of AMH also impacted pregnancy rates (OR: 1.22, CI: 1.03-1.53, p<0.001, Table 2).

The FSH dose that was used for ovarian stimulation (CC: 0.089, p=0.075) and female BMI (CC: -0.203, p=0.065) did not correlate with serum AMH levels.

The serum level of AMH did not impact embryo quality on days two or three or the chance of blastocyst formation. However, AMH levels affected oocyte quality (OR: 0.75, CI: 0.44-0.96, p<0.001, Table 3).

The presence of aggregates of smooth ERC (OR: 0.82, CI: 0.63-0.99, p=0.025), large PVS (OR: 0.84, CI: 0.76-0.93, p<0.001), PVS granularity (OR: 0.91, CI: 0.79-0.96, p<0.001), ZP abnormalities (OR: 0.85, CI: 0.73-0.94, p<0.001), and shape abnormalities (OR: 0.83, CI: 0.51-0.93, p=0.010) were affected by the serum level of AMH. The presence of other dysmorphisms, such as cytoplasm color, vacuoles in the ooplasm, retractive bodies, and fragmented PB was not affected by the level of AMH (Table 3).

DISCUSSION
Oocyte quality has been regarded as a variable that influences the implantation of derived embryos. It has been previously described that when cumulus cells are denuded for ICSI, more than 60% of all oocytes show at least one abnormal morphological characteristic (Braga et al., 2013). Considering that both extreme forms of ovarian response (low and hyper-response) may be associated with diminished oocyte quality (van Rooij et al., 2003; Figueira et al., 2011; Braga et al., 2012), we have hypothesized that lower levels of AMH might have a negative effect on oocyte and embryo development. Our results demonstrated that neither embryo quality on the cleavage stage nor the chance of blastocyst formation was correlated with AMH levels. However, the serum level of AMH was positively correlated with oocyte quality.

It remains unclear whether the correlation between AMH and the presence of oocyte defects is due to decreased secretion by granulosa cells in poor quality oocytes or due to a possible detrimental effect of low levels of AMH on oocyte quality. Indeed, AMH might play an important role in primordial follicle selection and cyclic growing follicle recruitment (Carlsson et al., 2006). Moreover, AMH might regulate the selection of the dominant follicle through the inhibitory effects of AMH on the initial recruitment of primary follicles from the resting primordial follicle pool (Durlinger et al., 2001) and through the regulation of FSH sensitivity in the human ovary (Kevenaar et al., 2007).

Our data also support previous reports on the prognostic value of AMH levels on female age (Broer et al., 2009; Nelson et al., 2011) and ovarian response (Broer et al., 2009). However, the inability to estimate embryo quality and blastocyst formation competence by AMH levels disagreed with the work of Silverstein et al. (2006), in which a relationship was reported between AMH levels and embryo morphology. In the mentioned study, the morphological assessment of cleavage stage embryos consisted of the evaluation of cell number, percent fragmentation, and blastomere symmetry. The presence of multinucleation and defects in the zona pelucida and cytoplasm was not evaluated. Moreover, it failed to define high/low-quality embryos or to adopt any form of embryo scoring criteria.

In our study, the serum level of AMH affected the presence of intra- and extracytoplasmic defects. This finding agreed with an elegant trial from Fanchin et al. (2007), in which a clinical model of monodominant follicle in vitro fertilization to determine whether AMH production by a single, preovulatory follicle, as assessed by follicular fluid AMH measurements, was positively related to oocyte and embryo development. A direct link was suggested between the amplitude of granulosa cells to produce AMH and the functional quality of the oocyte, as reflected by its competence to become an embryo with implantation potential.

Ebner et al. (2006) also demonstrated that serum levels of AMH were associated with oocyte quality in stimulated cycles. In their study, embryo quality was not estimated using baseline AMH levels, which was also in accordance with our evidence. However, the fertilization rate was not correlated with the level of AMH, which disagreed with the results of the present study.
Table 1. Pearson’s correlation coefficient between the serum level of Anti-Müllerian hormone and patient and cycle characteristics.

| Variable                              | Correlation coefficient | p       |
|---------------------------------------|-------------------------|---------|
| Maternal age                          | -0.279                  | <0.001  |
| Maternal BMI                          | -0.203                  | 0.065   |
| FSH dose                              | 0.089                   | 0.075   |
| Number of aspirated follicles         | 0.626                   | <0.001  |
| Number of retrieved oocytes           | 0.600                   | <0.001  |
| Number of retrieved MII mature oocytes| 0.588                   | <0.001  |
| Fertilization Rate                    | 0.595                   | 0.048   |
| Number of obtained embryos            | 0.495                   | <0.001  |
| Number of obtained high-quality embryos| 0.504                   | <0.001  |
| Number of transferred Embryos         | 0.221                   | <0.001  |
| Implantation Rate                     | 0.116                   | 0.031   |

AMH: Anti-Müllerian hormone.

Table 2. Binary regression analysis of the effect of the serum level of Anti-Müllerian hormone on embryo quality on days two or three, chance of blastocyst formation, and pregnancy odds

| Predictor variable | Response variable                  | P       | OR | CI: Lower | CI: Upper |
|--------------------|------------------------------------|---------|----|-----------|-----------|
| Serum level of AMH | Embryo quality on day two          | 0.846   | 1.01| 0.97      | 1.03      |
|                    | Embryo quality on day three        | 0.724   | 0.99| 0.73      | 2.19      |
|                    | Blastocyst formation              | 0.574   | 0.98| 0.54      | 1.96      |
|                    | Pregnancy                          | <0.001  | 1.22| 1.03-     | 1.53      |

AMH: Anti-Müllerian hormone.

Table 3. Binary regression analysis of oocyte dysmorphisms affected by the serum level of Anti-Müllerian hormone

| Predictor variable | Response variable                  | p       | OR | CI: Lower | CI: Upper |
|--------------------|------------------------------------|---------|----|-----------|-----------|
| Serum level of AMH | At least one oocyte defect          | <0.001  | 0.75| 0.44      | 0.96      |
|                    | Cytoplasm color                     | 0.056   | 0.79| 0.65      | 1.03      |
|                    | Vacuoles in the ooplasm             | 0.465   | 0.97| 0.91      | 1.09      |
|                    | Aggregates of smooth ERC            | 0.025   | 0.82| 0.63      | 0.99      |
|                    | Retractile Bodies                   | 0.256   | 0.83| 0.53      | 1.53      |
|                    | Large PVS                           | <0.001  | 0.84| 0.76      | 0.93      |
|                    | PVS granularity                     | <0.001  | 0.91| 0.79      | 0.96      |
|                    | ZP abnormalities                    | <0.001  | 0.85| 0.73      | 0.94      |
|                    | Shape abnormalities,                | 0.010   | 0.83| 0.51      | 0.93      |
|                    | Fragmented PB                       | 0.456   | 0.99| 0.86      | 1.09      |

AMH: Anti-Müllerian hormone, ERC: Endoplasmic reticulum cluster, PVS: perivitelline space, ZP: Zona pellucida, PB: Polar Body.

The process of fertilization is initiated by gamete fusion and can be considered to include all the events associated with egg activation until the time the egg is committed to embryonic development (Nixon et al., 2000). The observation that the level of AMH negatively affected fertilization and oocyte quality suggests a possible relationship between granulosa cell metabolism and oocyte developmental competence. Previous studies have shown that the degree of apoptosis of mural and cumulus granulosa cells negatively affects the developmental competence of the oocyte (Nakahara et al., 1997; Zeuner et al., 2003). Accordingly, human (Weenen et al., 2004) and animal (Bézard et al., 1987; Baarends et al., 1995) follicular atresia prevents the expression of AMH.

In this study, it is unclear why AMH serum levels affected fertilization rates and oocyte quality, but not embryo development. It may be suggested that, although the level of AMH has a significant negative effect on oocyte quality and fertilization capacity, once fertilized, oocytes do not show compromised developmental competence in vitro. Embryo genome is known to begin express between the four- and eight-cell stages of human embryo development. At this stage, the sperm-derived genes linked to embryo viability have also been disrupted (Tesarík et al., 1988).
In addition to fertilization, our results showed the existence of a relationship between level of AMH and chance of pregnancy. Loh & Maheshwari (2011) previously described that AMH fails to predict the odds of pregnancy. Nonetheless, some reported that extremely low levels of AMH are associated with non-pregnancy (La Marca et al., 2011) while others described moderate to reasonable pregnancy rates following extremely low levels of serum AMH (Lamazou et al., 2011; Weghofer et al., 2011). In our study, the chance of pregnancy and the number of obtained embryos, high-quality embryos, and transferred embryos were positively correlated with the level of AMH. Therefore, it might be argued that the correlation between AMH and pregnancy depends on the number of obtained oocytes and embryos available for transfer, rather than embryo quality. On the other hand, AMH levels also negatively impacted the implantation rate, which measures the number of transferred embryos.

These findings raised the question as to whether the worse outcomes observed for patients with lower AMH levels correlated with lower response to COS, decreased oocyte quality or both.

In conclusion, our findings indicated that the serum level of AMH is a useful predictor of ovarian response to COS, oocyte quality, fertilization, and implantation. However, although AMH levels might compromise pregnancy outcomes, lower levels of AMH do not impair the embryo developmental competence.

CONFLICT OF INTERESTS

The authors have no conflicts of interest to report.

Corresponding author:
Daniela Braga
Fertility Medical Group São Paulo/SP - Brazil
São Paulo, SP, Brazil.
E-mail: dbraga@fertility.com.br

REFERENCES

Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology. 1995;136:4951-62. PMID: 7588229 DOI: 10.1210/endo.136.11.7588229

Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18:73-91. PMID: 22068695 DOI: 10.1093/humupd/dmr039

Bézard J, Vigier B, Tran D, Mauléon P, Josso N. Immunocytochemical study of anti-Müllerian hormone in sheep ovarian follicles during fetal and post-natal development. J Reprod Fertil. 1987;80:509-16. PMID: 3309279

Braga DP, Setti AS, Figueira Rde C, Iaconelli A Jr, Borges E Jr. Contributing factors for the incidence of aneuploidy in older patients undergoing intracytoplasmic sperm injection cycles. J Assist Reprod Genet. 2012;29:911-6. PMID: 22644632 DOI: 10.1007/s10815-012-9795-x

Braga DP, Setti AS, Figueira Rde C, Machado RB, Iaconelli A Jr, Borges E Jr. Influence of oocyte dysmorphisms on blastocyst formation and quality. Fertil Steril. 2013;100:748-54. PMID: 23768966 DOI: 10.1016/j.fertnstert.2013.05.021

Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimüllerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91:705-14. PMID: 18321493 DOI: 10.1016/j.fertnstert.2007.12.013

Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21:2223-7. PMID: 16720622 DOI: 10.1093/humrep/dei165

de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77:357-62. PMID: 11821097 DOI: 10.1016/S0015-0282(01)02993-4

Durlinger AL, Grujters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891-9. PMID: 11606457 DOI: 10.1210/endo.142.11.8486

Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999;140:5789-96. PMID: 10579345 DOI: 10.1210/endo.140.12.7204

Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002;124:601-9. PMID: 12416998 DOI: 10.1530/rep.0.1240601

Ebnner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022-6. PMID: 16679324 DOI: 10.1093/humrep/dei127

Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ. Dynamic assays of inhibin B, anti-Müllerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20:3178-83. PMID: 16113044 DOI: 10.1093/humrep/dei203

Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, Taieb J. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab. 2007;92:1796-802. PMID: 17327387 DOI: 10.1210/jc.2006-1053

Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18:323-7. PMID: 12571168 DOI: 10.1093/humrep/deg042
Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Anti-mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2007;87:223-6. PMID: 17081531 DOI: 10.1016/j.fertnstert.2006.06.019

Talebian S, Licciardi F, Liu M, Grifo JA, Krey LC. Assessing anti-mullerian hormone (AMH) as a marker of ovarian response in anonymous oocyte donors: quantity or quality? Fertil Steril. 2008;90:S267. DOI: 10.1016/j.fertnstert.2008.07.1249

Tesarík J, Kopecný V, Plachot M, Mandelbaum J. Early morphological signs of embryonic genome expression in human preimplantation development as revealed by quantitative electron microscopy. Dev Biol. 1988;128:15-20. PMID: 2454852 DOI: 10.1016/0012-1606(88)90261-8

Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005;45:20-4. PMID: 15730360 DOI: 10.1111/j.1479-828X.2005.00332.x

Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065-71. PMID: 12456604 DOI: 10.1093/humrep/17.12.306

Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77-83. PMID: 14742691 DOI: 10.1093/molehr/gah015

Weghofer A, Dietrich W, Barad DH, Giecher N. Live birth chances in women with extremely low-serum anti-Müllerian hormone levels. Hum Reprod. 2011;26:1905-9. PMID: 21531994 DOI: 10.1093/humrep/derr134

Zeuner A, Müller K, Reguszynski K, Jewgenow K. Apoptosis within bovine follicular cells and its effect on oocyte development during in vitro maturation. Theriogenology. 2003;59:1421-33. PMID: 12527088 DOI: 10.1016/S0093-691X(02)01190-1